Since the revised EU GMP Annex 1 came into force, contamination control has moved from a supporting topic to a central regulatory expectation.
Under EU GMP Annex 1, sterile manufacturers are required to have a documented Contamination Control Strategy (CCS) in place.
But inspections are showing a clear shift in emphasis.
Inspectors are no longer asking whether a CCS exists. They are asking whether it works, in routine operation, under real conditions, and over time.
This is where many strategies begin to show strain. Not because teams lack understanding of Annex 1, but because the evidence behind the CCS doesn’t always stand up to scrutiny.
The weakest links are rarely missing procedures, they are blind spots in data, insight, and interpretation.
The weakest links are rarely missing procedures, they are blind spots in data, insight, and interpretation
Why EU GMP Annex 1 has changed the conversation
EU GMP Annex 1 defines a contamination control strategy as a planned set of controls, derived from product and process understanding, used to assure process performance and product quality. That definition matters.
It makes contamination control:
- Risk-based, not generic
- End-to-end, not siloed
- Evidence-led, not assumption-led
- Continuously reviewed, not static
A CCS is no longer a one-time deliverable. It is expected to function as a living system, supported by data that demonstrates a sustained state of control.
This is why environmental monitoring across cleanrooms, isolators, and other controlled environments has moved firmly into the inspection spotlight, not just as a compliance activity, but as a primary source of CCS evidence.
Under EU GMP Annex 1, a Contamination Control Strategy (CCS) is only as strong as the environmental monitoring data used to evidence it.
Where CCSs and environmental monitoring commonly break down
Most CCS documents look robust on paper. Weaknesses tend to appear in how